Economic Effect of Biosimilars Government Procurement on the Monoclonal Antibody Market in Russia
Keywords:
Biopharmaceutical market, biosimilars, eculizumab, bevacizumab, trastuzumab, government procurement, budget savings, monoclonal antibodyAbstract
Biopharmaceutical market, particularly monoclonal antibodies segment has been going through serious changes for the last ten years. Along with emergence of innovative drugs, new indications for existing medications and new ways of drug delivery, biosimilars, appear, whose main idea is not only to bring profit to pharmaceutical companies but also increase availability of modern ways of life-threatening diseases treatment. Key competitive advantage of biosimilars is usually a discounted price in comparison with an originator drug. This article tries to evaluate the economic effect of approved monoclonal antibody biosimilars procurement in 2018 and 2019. According to the study results weighted average prices for two out of seven biosimilars appeared to be significantly lower than prices for original drugs (Avegra — 78,53% and Elizaria — 76,6% from originator price); four biosimilars (Infliximab Biocad — 94,12%, Flammegis — 98,42. Acellbia — 98,85, Redditux — 97,33% from riginators price) did not demonstrate significant discounts; one biosimilar (Herticad — 115,31% from weighted average price of original drug) turned out to be more expensive than its competitor Herceptin. The economic effect in terms of the amount of savings due to biosimilar procurement was calculated based on the analysis of weighted average prices. Thus, the greatest contribution to the budget savings was made by the Elizaria, which made it possible to use approximately 3.3 billion rubles more effectively during 2018 and 2019. In addition to Elizaria, a significant contribution was made by the procurement of Avegra, which saved 2.9 billion rubles. The procurement of four other biosimilars saved about 246 million rubles, while the purchase of Herticad required an additional 1.4 billion rubles.
References
Борисов В.Е., Борисов Е.Е., Ноговицын Р.Р., Сафонова С.Л. Основные направления развития высокотехнологичных инновационных биотехнологических производств // Проблемы современно экономики. 2015. № 1(53). С. 228–231.
Горкавенко Ф.В., Никитина А.В., Сайбель Е.С., Авксентьева М.В., Сура М.В.,
Федяев Д.В. Динамика цен и потребления противоопухолевых лекарственных препаратов в сегменте государственных закупок после выхода на российский фармацевтический рынок воспроизведенных препаратов и биоаналогов // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2019. Т. 2. № 2. С. 115–124. DOI: https://doi.org/10.17749/2070-4909.2019.12.2.115-124.
Дзанаева А.В., Омельяновский В.В., Кагермазова С.А. Инновационные препараты в системе льготного лекарственного обеспечения // Медицинские технологии. Оценка и выбор. 2015. № 3. С. 41–46.
Ельцова Е.А., Раменская Г.В., Смолярчук Е.А., Бушманова А.В. Биосимиляры — препараты будущего // Фармакокинетика и фармакодинамика. 2015. № 1. С. 12–15.
Кирсанова О.В., Омельяновский В.В. Анализ проблемы регулирования доступа к биосимилярам и пути решения // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2018. Т. 11. № 1. С. 50–55. DOI: https://doi.org/10.17749/2070- 4909.2018.11.1.050-055.
Сарапкин И.Н. Биоаналоги в России и за рубежом: конституционно-правовой аспект // Конституционное и муниципальное право. 2016. № 6. С. 29–33.
Стрельцова Е.А. Патентная активность в сфере биотехнологий // Форсайт. 2014. Т. 8. № 1. С. 52–65.
Уваров Д.А. Анализ российского рынка инновационных препаратов на основе моноклональных антител // Инновации и инвестиции. 2020. № 5. C. 328–332
Филиппова И. Биоаналоги: растущая доступность // Журнал «Ремедиум». 2014. № 10. С. 55–56. DOI: http://dx.doi.org/10.21518/1561-5936-2014-10-55-56.
Attridge J. Innovation Models in Biopharmaceutical Sector // International Journal of Innovation Management. 2007. Vol. 11. Is. 02. P. 215–243. DOI: https://doi.org/10.1142/S1363919607001746.
Calo-Fernández B., Martínez-Hurtado J.L. Biosimilars: Company Strategies to Capture Value from the Biologics Market // Pharmaceuticals. 2012. Vol. 5. Is. 12. P. 1393–1408. DOI: https://doi.org/10.3390/ph5121393.
Dutta B., Huys I., Vulto A.G., Simoens S. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! // BioDrugs. 2020. No. 34. P. 159–170. DOI: https://doi.org/10.1007/s40259-019-00395-w.
Heredia E., Ribeiro A. Discounts Offered by First and Subsequent Biosimilars in the US, EU and Latam: Impact Trends of Originator Starting Price, Market Dynamics and Regulations // Value in Health. 2018. No. 21. P. 103–104. DOI: https://doi.org/10.1016/j.jval.2018.04.700.
Simoens S. Biosimilar Medicines and Cost-Effectiveness // ClinicoEconomics and Outcomes Research. 2011. Vol. 3. P. 29–36. DOI: https://doi.org/10.2147/CEOR.S12494.
Sitte H., Freissmuth M. Biosimilars versus Generics: Scientific Basics and Clinical Implications // memo — Magazine of European Medical Oncology. 2013. No. 6. P. 202–206. DOI: https://doi.org/10.1007/s12254-013-0094-8.
